Centessa Pharmaceuticals (CNTA) EBIT Margin (2025)
Centessa Pharmaceuticals (CNTA) reported EBIT Margin of 205.18% for Q1 2025.
Centessa Pharmaceuticals (CNTA) EBIT Margin (2025) Analysis & Trends
Centessa Pharmaceuticals (CNTA) has 1 years of EBIT Margin data on file, last reported at 205.18% in Q1 2025.
- EBIT Margin for Q1 2025 came in at 205.18%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 1384.61% (changed N/A YoY), and the FY2025 annual result was 1384.61%, changed N/A from the prior year.
- EBIT Margin steadied at 205.18% in Q1 2025 per CNTA's latest filing.
- Over five years, EBIT Margin peaked at 205.18% in Q1 2025 and troughed at 205.18% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Centessa Pharmaceuticals | 6.10 Bn | 6.10 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -205.18% |